U.S. Markets open in 36 mins

Pluristem Therapeutics Inc. (PSTI)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
2.9300-0.0300 (-1.01%)
At close: 4:00PM EDT

Pluristem Therapeutics Inc.

Building No. 5
MATAM Advanced Technology Park
Haifa 31905
Israel
972 7 4710 8600
http://www.pluristem.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees146

Key Executives

NameTitlePayExercisedYear Born
Mr. Zami AbermanExec. Chairman501.24kN/A1954
Mr. Yaky YanayPres, CEO & Director350.29kN/A1971
Ms. Chen Franco-YehudaCFO, Treasurer & Sec.207.69kN/A1984
Mr. Lior RavivVP of Operations & Devel.N/AN/AN/A
Ms. Dana RubinDirector of Investor RelationsN/AN/AN/A
Ms. Efrat Livne-HadassVP of HRN/AN/AN/A
Dr. Nitsan Halevy M.D.Chief Medical OfficerN/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Pluristem Therapeutics Inc., together with its subsidiary, Pluristem Ltd., operates as a bio-therapeutics company in Israel. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD cells, which is Phase III clinical trial for the treatment of critical limb ischemia (CLI) in patients unsuitable for revascularization, recovery after surgery for hip fracture, and acute radiation syndrome (ARS), as well as peripheral and cardiovascular, and orthopedic diseases. It also develops PLX-R18 cells that is in Phase I clinical trial for incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as conducts various animal studies for the evaluation of PLX-R18 for the treatment of ARS. The company has a license and commercialization agreement for conducting clinical trials and commercialization of its PLX-PAD product in South Korea related to the treatment CLI and intermittent claudication; and nTRACK, a collaborative project with Leitat to examine gold nano particles labeling of stem cells. It also has collaboration agreements with the NASA's Ames Research Center to evaluate the potential of PLX cell therapies in preventing and treating medical conditions caused during space missions; and BIH Center for Regenerative Therapy and Berlin Center for Advanced Therapies to expand its framework and research agreement, as well as conduct a joint project evaluating the therapeutic effects of the registrant's patented PLX cell product candidates for treatment of the respiratory and inflammatory complications associated with the COVID-19 coronavirus. Pluristem Therapeutics Inc. was founded in 2001 and is based in Haifa, Israel.

Corporate Governance

Pluristem Therapeutics Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.